ATE375362T1 - Von cyclophilin b abstammende tumorantigen- peptide - Google Patents

Von cyclophilin b abstammende tumorantigen- peptide

Info

Publication number
ATE375362T1
ATE375362T1 AT99926783T AT99926783T ATE375362T1 AT E375362 T1 ATE375362 T1 AT E375362T1 AT 99926783 T AT99926783 T AT 99926783T AT 99926783 T AT99926783 T AT 99926783T AT E375362 T1 ATE375362 T1 AT E375362T1
Authority
AT
Austria
Prior art keywords
tumor antigen
antigen peptides
peptides derived
cyclophilins
cyclophilin
Prior art date
Application number
AT99926783T
Other languages
English (en)
Inventor
Kyogo Itoh
Shinya Gomi
Original Assignee
Kyogo Itoh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kyogo Itoh filed Critical Kyogo Itoh
Application granted granted Critical
Publication of ATE375362T1 publication Critical patent/ATE375362T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57488—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds identifable in body fluids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/90—Isomerases (5.)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • General Engineering & Computer Science (AREA)
  • Analytical Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Food Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
AT99926783T 1998-06-25 1999-06-24 Von cyclophilin b abstammende tumorantigen- peptide ATE375362T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP17844998 1998-06-25

Publications (1)

Publication Number Publication Date
ATE375362T1 true ATE375362T1 (de) 2007-10-15

Family

ID=16048723

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99926783T ATE375362T1 (de) 1998-06-25 1999-06-24 Von cyclophilin b abstammende tumorantigen- peptide

Country Status (14)

Country Link
US (2) US7041297B1 (de)
EP (1) EP1090924B8 (de)
JP (1) JP4413429B2 (de)
KR (1) KR100653590B1 (de)
CN (1) CN1318447C (de)
AT (1) ATE375362T1 (de)
AU (1) AU749544B2 (de)
CA (1) CA2331761A1 (de)
DE (1) DE69937294T2 (de)
ES (1) ES2294844T3 (de)
ID (1) ID27788A (de)
NZ (1) NZ508996A (de)
TW (1) TWI228128B (de)
WO (1) WO1999067288A1 (de)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7105306B1 (en) * 2000-08-10 2006-09-12 Trustees Of The University Of Pennsylvania Methods and compositions for modulating somatolactogenic functions
EP1212078B1 (de) * 1999-09-10 2005-06-22 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Ant-1 als therapeutisches zielmolekül
EP1263442A1 (de) * 2000-01-24 2002-12-11 Trustees Of Tufts College Tetracycline verbindungen zur behandlung von mit cryptosporidium parvum gebundenen krankheiten
ATE264295T1 (de) * 2000-05-15 2004-04-15 Paratek Pharm Innc 7-substituierte kondensierte ring-tetrazyclin- verbindungen
AU2001268475A1 (en) * 2000-06-16 2002-01-02 Trustees Of Tufts College 7-phenyl-substituted tetracycline compounds
AU2002365120A1 (en) 2001-08-02 2003-07-15 Paratek Pharmaceuticals, Inc. Medicaments
EP1548032B9 (de) 2002-09-12 2009-10-28 Oncotherapy Science, Inc. Kdr-peptide und diese enthaltende impfstoffe
US20080254445A1 (en) * 2003-09-22 2008-10-16 Kyogo Itoh Prognosis in Cancer Patients Vaccinated with a Cancer Antigen Peptide-Associated Agent
TWI261038B (en) * 2004-08-11 2006-09-01 Bo-Cheng Chen Bicycle gear-shifting handgrip
EP2301916A3 (de) 2004-10-25 2011-09-28 Paratek Pharmaceuticals, Inc. 4-Aminotetracycline und Verfahren zu ihrer Verwendung
JP4829961B2 (ja) 2006-05-01 2011-12-07 日立化成工業株式会社 プロスタシン部分ペプチド及び抗プロスタシン抗体
WO2008045507A2 (en) 2006-10-11 2008-04-17 Paratek Pharmaceuticals, Inc. Substituted tetracycline compounds for treatment of bacillus anthracis infections
US20100009920A1 (en) 2006-12-13 2010-01-14 Yusuke Nakamura Ttk as tumor marker and therapeutic target for lung cancer
CA2678432A1 (en) 2007-02-16 2008-08-21 Oncotherapy Science, Inc. Vaccine therapy for choroidal neovascularization
TWI434853B (zh) 2007-04-11 2014-04-21 Oncotherapy Science Inc 腫瘤血管內皮標誌８胜肽及包含此胜肽之疫苗
BRPI0816150A2 (pt) 2007-08-24 2019-09-24 Oncotherapy Science Inc genes relacionados com câncer, cdca5, eph47, stk31 e w-dhd1.
WO2009038026A1 (ja) 2007-09-18 2009-03-26 Kurume University Ｃｔｌ誘導剤組成物
CN101868469B (zh) 2007-11-29 2014-04-02 埃科特莱茵药品有限公司 膦酸衍生物及其作为p2y12受体拮抗剂
TWI526219B (zh) 2008-06-19 2016-03-21 腫瘤療法 科學股份有限公司 Ｃｄｃａ１抗原決定位胜肽及含此胜肽的疫苗
DE102008060549A1 (de) 2008-12-04 2010-06-10 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Wirkstoff-Peptid-Konstrukt zur extrazellulären Anreicherung
TWI539160B (zh) 2008-12-05 2016-06-21 腫瘤療法 科學股份有限公司 Ｗｄｒｐｕｈ抗原決定位胜肽以及含此胜肽之疫苗
TWI469791B (zh) 2009-02-18 2015-01-21 Oncotherapy Science Inc Ｆｏｘｍ１胜肽以及含此胜肽之疫苗
HUE030856T2 (en) 2009-03-18 2017-06-28 Oncotherapy Science Inc NEIL3 peptides and vaccines containing them
TWI507204B (zh) 2009-05-26 2015-11-11 Oncotherapy Science Inc Ｃｄｃ４５ｌ胜肽與含此胜肽之疫苗
TW201136604A (en) 2009-12-14 2011-11-01 Oncotherapy Science Inc TMEM22 peptides and vaccines including the same
JP5838482B2 (ja) 2010-03-11 2016-01-06 オンコセラピー・サイエンス株式会社 Ｈｊｕｒｐペプチドおよびそれを含むワクチン
DK2738255T3 (en) 2011-07-29 2017-03-06 Univ Tokushima ERAP1-Derived Peptide and its Use
MX350220B (es) 2011-08-12 2017-08-30 Oncotherapy Science Inc Peptidos de mphosph1 y vacunas que incluyen los mismos.
UA114298C2 (uk) 2011-10-28 2017-05-25 Онкотерапі Саєнс, Інк. Пептид торк та вакцина, що його містить
EP2872530A4 (de) 2012-07-10 2016-04-06 Oncotherapy Science Inc Kif20a-epitop-peptide für th1-zellen und impfstoffe damit
JP6255594B2 (ja) 2012-07-10 2018-01-10 オンコセラピー・サイエンス株式会社 Ｔｈ１細胞のＬＹ６Ｋエピトープペプチドおよびこれを含有するワクチン
RU2663350C2 (ru) 2012-09-11 2018-08-03 Онкотерапи Сайенс, Инк. Пептиды ube2t и содержащие их вакцины
TWI658049B (zh) 2013-03-12 2019-05-01 腫瘤療法 科學股份有限公司 Ｋｎｔｃ２胜肽及含此胜肽之疫苗
ES2796301T3 (es) 2013-10-21 2020-11-26 Taiho Pharmaceutical Co Ltd Nuevo péptido con cuatro epítopos CTL unidos
MX2017001651A (es) 2014-08-04 2017-04-27 Oncotherapy Science Inc Peptido derivado de urlc10 y vacuna que lo contiene.
CN111925431B (zh) 2014-08-04 2025-04-15 肿瘤疗法科学股份有限公司 Koc1衍生的肽和包含它们的疫苗
CN107074908B (zh) 2014-08-04 2021-10-15 肿瘤疗法科学股份有限公司 Cdca1衍生的肽和含有它们的疫苗
CN112940076B (zh) 2015-10-08 2025-05-02 肿瘤疗法科学股份有限公司 Foxm1衍生的肽和包含它们的疫苗
US12251447B2 (en) 2018-06-29 2025-03-18 Taiho Pharmaceutical Co., Ltd. Combined formulation comprising four linked cytotoxic T lymphocyte (CTL) epitopes and a PD-1 pathway inhibitor and methods of use thereof to treat cancer
TW202023581A (zh) 2018-08-02 2020-07-01 日商腫瘤療法 科學股份有限公司 來自cdca1的胜肽及含有此的疫苗
US20220098256A1 (en) 2018-11-30 2022-03-31 Tokushima University Therapeutic agent for breast cancer comprising big3-phb2 interaction-inhibiting peptide derived from phb2
US20230055953A1 (en) 2019-12-26 2023-02-23 Taiho Pharmaceutical Co., Ltd. Agent for adjuvant therapy
CN115078727A (zh) * 2022-07-13 2022-09-20 首都医科大学附属北京胸科医院 一种预测癌症免疫治疗效果的标志物、试剂盒与应用
DE102022118517A1 (de) 2022-07-25 2024-01-25 Dennis Reitmeir Liegestützvorrichtung mit drehbaren Griffeinheiten
CN115372618B (zh) * 2022-09-19 2025-01-14 首都医科大学附属北京胸科医院 一种检测蛋白标志物水平的试剂在制备用于评估肿瘤治疗效果的诊断产品中的应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0326067A3 (de) * 1988-01-26 1991-04-17 The Du Pont Merck Pharmaceutical Company Verwendung von Cyclophylin als Entzündungshemmer und Immunmodulator
SG52492A1 (en) * 1992-08-07 1998-09-28 Cytel Corp Hla binding peptides and their uses
JPH09151200A (ja) * 1995-09-29 1997-06-10 Ajinomoto Co Inc ヒト胃癌に対する免疫応答を誘導できるペプチド及び該ペプチドを含むヒト胃癌治療、予防剤
US5840839A (en) * 1996-02-09 1998-11-24 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Alternative open reading frame DNA of a normal gene and a novel human cancer antigen encoded therein

Also Published As

Publication number Publication date
WO1999067288A9 (fr) 2000-03-30
KR20010053180A (ko) 2001-06-25
CA2331761A1 (en) 1999-12-29
WO1999067288A1 (en) 1999-12-29
EP1090924A4 (de) 2002-07-10
DE69937294D1 (de) 2007-11-22
DE69937294T2 (de) 2008-07-03
AU749544B2 (en) 2002-06-27
US7368107B2 (en) 2008-05-06
EP1090924A1 (de) 2001-04-11
AU4392699A (en) 2000-01-10
US7041297B1 (en) 2006-05-09
HK1067645A1 (en) 2005-04-15
CN1525980A (zh) 2004-09-01
ID27788A (id) 2001-04-26
NZ508996A (en) 2003-09-26
EP1090924B1 (de) 2007-10-10
CN1318447C (zh) 2007-05-30
ES2294844T3 (es) 2008-04-01
US20060008463A1 (en) 2006-01-12
EP1090924B8 (de) 2007-11-21
KR100653590B1 (ko) 2006-12-04
JP4413429B2 (ja) 2010-02-10
TWI228128B (en) 2005-02-21

Similar Documents

Publication Publication Date Title
ATE375362T1 (de) Von cyclophilin b abstammende tumorantigen- peptide
BR9907259A (pt) Compostos para terapia e diagnóstico de câncer de pulmão e processos para o seu uso
EP0570916A3 (de) Menschliches rekombinantes Serum-Albumin, Verfahren zur dessen Herstellung und diese enthaltende pharmazeutischen Präparate.
EP2022800A3 (de) Zusammensetzungen zur Behandlung und Diagnose von Eierstockkrebs
DE69738754D1 (de) Hemmer der interaktion zwischen p53 und mdm2
NZ516381A (en) Lung tumor proteins in the therapy and diagnosis of lung cancer
BR9707819A (pt) Imunogenos peptidicos
WO1998037093A3 (en) Compounds for immunotherapy of prostate cancer and methods for their use
WO2000078344A8 (en) Prion protein peptides and uses thereof
AU2001235006A1 (en) Prophylactic and therapeutic monoclonal antibodies
WO2000029574A3 (en) Inflammation-associated genes
ATE295423T1 (de) Phosphodiesterase 8
WO1997018790A3 (en) Therapeutic and diagnostic agents for the treatment of microbial infections
WO2001018046A3 (en) Ovarian tumor sequences and methods of use therefor
EP1762620A3 (de) Antigene aus Cryptosporidium parvum, Antikörper dagegen und diagnostische und therapeutische Zusammensetzungen
NZ510154A (en) A tumour antigen protein and gene therefor, tumour antigen peptides and derivatives thereof in medicaments and prophylactics
WO2001029220A3 (en) Mage-a12 antigenic peptides and uses thereof
EP1364657A4 (de) Mittel gegen tumoren in hämatopoetischen organen
ATE310828T1 (de) Implantat und vektor zur behandlung von erworbenen krankheiten
ZA971403B (en) Tumor rejection antigens presented by HLA-B44 molecules, and uses thereof.
DE69700983D1 (de) Ligandgerichtete enzyme-prodrug therapie
WO2000001729A3 (en) Synthetic peptides and pharmaceutical compositions comprising them for diagnosis and treatment of anti-phospholipid syndrome
WO2000052045A3 (en) Mage-3 derived immunogenic peptides presented by mhc of class ii and the use thereof
EP1103561A4 (de) Hla-a2 beschränktes tumorantigen-peptid, das von sart-1 abstammt
WO2000060082A3 (en) Vesicle associated proteins

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties